Tag: AbbVie

Approved use of IMBRUVICA with Obinutuzumab for CLL/SLL

AbbVie, a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) in combination with obinutuzumab ...

AbbVie and J&J’s Pancreatic Cancer Drug Failed Trial

AbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has hit a snag. In the phase III RESOLVE trial, Imbruvica (ibrutinib) was no...

AbbVie and Tizona to Develop Antibody for Cancer Treatment

AbbVie, a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc., a privately held immunotherapy company, announced on Jan. 3, 2019 that they have entered into a global, strate...

AbbVie presses charges against UK National Health Service

abbvie office
Abbvie, a global pharmaceutical company, is claiming that National Health Service (UK) breached procurement rules during a process seeking suppliers for hepatitis C treatment.

AbbVie and Morphic Therapeutic to cooperate on antifibrotic medications

abbvie
AbbVie and Morphic Therapeutic (Massachusetts, USA) announced that the companies have entered into a research and development collaboration designed to advance a number of oral integrin therapeutics.

AbbVie obtains an exclusive license for novel antibody from Dutch biotech

biotech
argenx, a clinical-stage biotechnology company, announced the exercise by AbbVie of its exclusive license option to develop and commercialize ARGX-115.

Tolero Pharmaceuticals enters into clinical research collaboration with AbbVie

research
Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie exploring the potential of combination therapy with AbbVie's venetoclax and Tolero's alvocidib.

AbbVie and R-Pharm will launch the full-cycle manufacturing of Kaletra in Russia

R-Pharm
AbbVie, a global research biopharmaceutical company, and R-Pharm Group announced the completion of technology transfer for manufacturing Kaletra intended for treatment of HIV/AIDS infection in adult patients.

AbbVie and Calibr started a CAR-T collaboration

abbvie
AbbVie and Calibr, a nonprofit drug discovery division of Scripps Research, announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors.

AbbVie reached a resolution in intellectual property-related dispute

abbvie
AbbVie announced it reached a global resolution for all intellectual property-related litigation with the two companies regarding its biosimilar Imraldi (adalimumab).

Russia approves Venclexta for the treatment of CLL

abbvie
AbbVie announced that the Russian Ministry of Health approved Venclexta (venetoclax), a drug, for oral administration. The drug is a potent selective inhibitor of antiapoptotic protein of B-cell lymphoma.

Biogen and Abbvie pull their multiple sclerosis drug off the worldwide market

biogen
Biogen and AbbVie announced the voluntary withdrawal of ZINBRYTA for relapsing multiple sclerosis. The European Medicines Agency started an urgent review following the reports of eight cases of inflammation of the brain.

AbbVie and Voyager Therapeutics set up a partnership

abbvie office
AbbVie and Voyager Therapeutics entered into a collaboration to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

AbbVie launches Biologics Manufacturing Facility in Singapore

abbvie
AbbVie, a global research and development-based biopharmaceutical company, opened its Biologics Manufacturing Facility

AbbVie and Turnstone Biologics starts cooperation on viral immunotherapies

abbvie office
AbbVie and Turnstone Biologics announced a research, option and license agreement whereby AbbVie obtained an option to license up to three of Turnstone's next viral immunotherapies

AbbVie will have to pay $150 million after losing a lawsuit in USA

abbvie office
A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel